Catalyst Capital Advisors LLC Sells 1,725 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Catalyst Capital Advisors LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 26.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,800 shares of the company’s stock after selling 1,725 shares during the period. Catalyst Capital Advisors LLC’s holdings in TransMedics Group were worth $754,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Harbor Capital Advisors Inc. grew its holdings in TransMedics Group by 48.2% in the third quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company’s stock worth $1,407,000 after purchasing an additional 2,916 shares during the period. Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. New York State Teachers Retirement System acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at about $1,217,000. State of Alaska Department of Revenue bought a new stake in TransMedics Group in the 3rd quarter valued at about $2,560,000. Finally, Louisiana State Employees Retirement System acquired a new position in TransMedics Group during the 3rd quarter worth approximately $2,528,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $83.00 on Wednesday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a 50-day moving average of $136.94 and a 200-day moving average of $139.95. TransMedics Group, Inc. has a one year low of $40.01 and a one year high of $177.37. The company has a market cap of $2.79 billion, a P/E ratio of 88.30 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter last year, the business posted ($0.12) EPS. The company’s quarterly revenue was up 63.7% on a year-over-year basis. Equities research analysts forecast that TransMedics Group, Inc. will post 1.08 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,208 shares of company stock valued at $7,853,165. 7.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Canaccord Genuity Group reduced their price objective on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Robert W. Baird decreased their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of “Buy” and a consensus target price of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.